Genetically-directed Sparse Neuronal Labeling in BAC Transgenic Mice through Mononucleotide Repeat Frameshift

Xiao-Hong Lu1,2,† & X. William Yang1,2

Mosaicism with Repeat Frameshift (MORF) allows a single Bacterial Artificial Chromosome (BAC) transgene to direct sparse labeling of genetically-defined neuronal populations in mice. The BAC transgene drives cell-type-specific transcription of an out-of-frame mononucleotide repeat that is placed between a translational start codon and a membrane-bound fluorescent protein lacking its start codon. The stochastic frameshift of the unstable repeat DNA in a subset of BAC-expressing neurons results in the in-frame translation of the reporter protein hence the sparse neuronal labeling. As a proof-of-concept, we generated D1-dopamine receptor (D1) BAC MORF mice that label about 1% striatal D1-expressing medium spiny neurons and allow visualization of their dendrites. These mice enable the study of D1-MSN dendrite development in wildtype mice, and its degeneration in a mouse model of Huntington’s disease.

One major challenge to study the mammalian brain is to visualize and perturb genetically-defined neurons at single-cell resolution. Several genetic methods have been developed to achieve sparse labeling of single neurons, enabling the study of the relationship between neuronal morphology and neuronal function or dysfunction1,2. These current methods, however, have certain limitations. For example, transgene promoter silencing due to random chromosomal insertions (e.g. Thy1 promoter transgene) is not readily applicable to other promoters to label diverse cell types. Also, low-efficiency and inducible site-specific recombination based methods may require the generation and crossing of multiple transgenic mouse lines with labeling frequency that may be variable and difficult to control.

Recent advances in transgenic or genome targeting technologies provide reliable genetic methods to express reporter genes (e.g. fluorescent proteins) in endogenous-like patterns in specific neuronal cell types in mice1,3. However, such genetic labeling in a densely packed neuronal cell population often precludes the visualization of their detailed morphology (i.e. dendrites and axons). Thus, a simple method is still lacking to readily generate transgenic mice, based on genetic constructs with proven neuronal cell-type specificity, but substantially reduced labeling frequency to confer sparse and stochastic (random) labeling of defined neurons for morphological analyses.

Microsatellite repeats (e.g. mono-, di- or tri-nucleotides) are ubiquitous but non-randomly distributed across all genomes and are prone to frameshift mutations4,5. The frequency of such frameshifts may be dependent on repeat type, length, and other cell-type-specific factors (e.g. mismatch repair efficacy)6. In rare cases, microsatellite repeats exist in the coding regions of genes and may cause neurological disorders and cancer when frameshift occurs3,7. To date, there are a few mouse genetic studies that take advantage of mononucleotide repeat frameshift to study frameshift mutation rates in vivo8–10, or inducing mosaic Cre expression in intestinal cells11,12. These studies did not reveal the potential of this approach for genetically directed sparse neuronal labeling, because the frameshift rate for G11 repeat in the brain is about $10^{-4}$ to $10^{-5}$ (Ref 8–10), which is much lower than the desirable sparse labeling frequency of about 1% neurons as in the classical Golgi method2.

1. Center for Neurobehavioral Genetics, Semel Institute for Neuroscience & Human Behavior, Los Angeles, CA 90095, USA.
2. Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.
3. Present address: Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, 71130, USA. Correspondence and requests for materials should be addressed to X.W.Y. (email: xwyang@mednet.ucla.edu)
**Results**

In this study, we reasoned that a long mononucleotide repeat (i.e. G22) might be combined with a proven neuronal cell-type-specific genetic construct such as a BAC transgene to achieve the sparse neuronal labeling at a desirable frequency to allow single neuron morphological studies. As a proof-of-concept for the MORF strategy, we used the murine dopamine receptor D1 (Drd1a) BAC that drives transgene expression in the direct-pathway medium spiny neurons (i.e. D1-MSNs)\(^3\). This is one of two major striatal projection neuron cell types that mediate basal ganglia function in motor control and learning\(^13\). Dysfunction or degeneration of such neuronal pathways have been implicated in major neurological and psychiatric disorders including Huntington’s disease (HD)\(^13\).

The original Drd1a-BAC-EGFP mice label the entire D1-MSN population precluding visualization of individual neuronal morphology\(^3\). To test the MORF strategy, we used the murine dopamine receptor D1 (Drd1a) BAC to insert a repeat of 22 deoxyguanines (G\(_{22}\)) between the ATG initiation codon and a membrane-tethered farnesylated GFP (fGFP), with this cassette inserted into murine Drd1a BAC (Drd1a-bacMORF-IGFP). In D1-MSNs without G\(_{22}\) frameshift to G3n frame, fGFP is not expressed. Only neurons with frameshift of G\(_{22}\) to G3n (e.g. 21, 18) will express fGFP with a small N-terminal polyglycine tag (translated from G3n). PA: Polyadenylation signal. (b) Schematics to illustrate that mitotic instability of the mononucleotide repeat during neurogenesis (mitosis) could render the out-of-frame (OF) G\(_{22}\) to undergo a frameshift mutation to allow the fluorescent marker protein to be reverted into in-frame (IF), and therefore the expression of the marker to label a small clonal lineage of cells. In some circumstances (e.g. damaged DNA undergoing mismatch repair), such IF reversion could happen in post-mitotic single neurons.

We performed pronuclear injections to create two Drd1a-bacMORF-IGFP (or Drd1a-bacMORF) founder mice, which we subsequently backcrossed and maintained as two lines (A and B line) on a C57BL/6J background. The transgenic mice were born at a Mendelian ratio and lack apparent behavioral phenotypes or pathology (data not shown). We quantified the transgene copy number and found A line has 3 copies and B line has one copy of the BAC transgene (Supplementary Fig. S1). We next performed GFP immunofluorescent staining of adult Drd1a-bacMORF mice and found that sparse labeling of a subset of striatal neurons with characteristic MSN morphology in both lines (Fig. 2a and c, Supplementary Fig. S2), a pattern that is distinct from the GENSAT Drd1a-EGFP mice (Fig. 2b). The sparsely labeled neurons, which consisted of single neurons or small cluster of neurons (likely clones), are located in both dorsal and ventral striatum, and their dendritic structures can be clearly visualized (Fig. 2). The distribution of the labeled single or small cluster of neurons appears random throughout the striatum, consistent with stochastic labeling of the MORF method. Since the fluorescent signal for the labeled neurons is not bright enough for direct imaging, immunostaining was necessary for optimal visualization (see Methods). To confirm that the labeled MSNs are indeed D1-MSNs, we crossed Drd1a-bacMORF mice with Drd1a-BAC-tdTomato mice\(^14\), which selectively express tdTomato in D1-MSNs. The double transgenic mice showed that all of the sparsely labeled neurons in Drd1a-bacMORF mice are also positive for tdTomato (Fig. 2d,e), demonstrating the sparse labeling of D1-MSNs in the Drd1a-bacMORF mice. Importantly,

---

**Figure 1. Illustration of the Mosaicism with Repeat Frameshift (MORF) Strategy for Genetically Directed Sparse and Stochastic Labeling of Single Neurons in the Mouse Brain.** (a) A mononucleotide G\(_{22}\) repeat was inserted between translational initiation codon and farnesylated GFP (fGFP), with this cassette inserted into murine Drd1a BAC (Drd1a-bacMORF-IGFP). In D1-MSNs without G\(_{22}\) frameshift to G3n frame, fGFP is not expressed. Only neurons with frameshift of G\(_{22}\) to G3n (e.g. 21, 18) will express fGFP with a small N-terminal polyglycine tag (translated from G3n). PA: Polyadenylation signal. (b) Schematics to illustrate that mitotic instability of the mononucleotide repeat during neurogenesis (mitosis) could render the out-of-frame (OF) G\(_{22}\) to undergo a frameshift mutation to allow the fluorescent marker protein to be reverted into in-frame (IF), and therefore the expression of the marker to label a small clonal lineage of cells. In some circumstances (e.g. damaged DNA undergoing mismatch repair), such IF reversion could happen in post-mitotic single neurons.
The quantification of the double transgenic mice showed the D1-MSN-specific labeling efficiency of about 0.978 ± 0.586% in these mice.

The incorporation of the membrane-tethered fGFP in the MORF method should facilitate the visualization and reconstruction of fine anatomical structures such as the dendrites for 3-dimensional (3D) reconstruction. Indeed, immunofluorescent staining in Drd1a-bacMORF mice revealed the details of dendritic architecture that can be readily reconstructed in 3D using Neurolucida (MicroBrightField; Fig. 3a,b), which in turn allows quantitative morphological analyses. Moreover, the MORF method also allows visualization of at least a...
Figure 3. Imaging and 3D Reconstruction of Detailed Dendritic and Spine Structures in Single Labeled D1-MSNs in Drd1a-bacMORF-fGFP Mice. The MORF method can be used to visualize the dendritic structures of D1-MSNs. (a) A projection of stacked confocal images of a single striatal D1-MSN labeled by the MORF method (scale bar = 10 μm). (b) A 3D reconstruction of the dendrite and spine structures using Neurolucida. (c) A projection of stacked confocal images of the dendritic spines from the D1-MSN depicted in 3A. Structures of spines can be visualized from the images (scale bar = 1 μm). (d–f) A comparison of the immunohistochemical staining of striatal D1-MSNs labeled by MORF ((d,e) scale bar = 10 μm) and MSNs labeled by the Golgi method ((f) scale bar = 10 μm). Striatal MSNs stained by the Golgi method (f) often are clustered with overlapping dendritic structures from multiple MSNs. Immunostaining for GFP in Drd1a-bacMORF-fGFP mice (d and e) show the labeling of small clusters (d) or single (e) D1-MSNs with a detailed dendritic structure for individual labeled neurons. (g,h) Quantitative comparison of the immunohistochemical staining of striatal D1-MSNs labeled by MORF and by biocytin microinjection into D1-MSNs in GENSAT Drd1a-BAC-GFP mice. Neurolucida and NeuroExplorer Suites (MicroBrightField) were used for 3D reconstruction of the dendritic structures of D1-MSNs labeled by the two methods, and for quantitation using Sholl analysis for intersections (branching) and dendritic length. Two-way ANOVA factored with labeling methods and distance to cell body could not detect significant difference between two methods (n = 5 for each genotype; Length: F = 0.992, P = 0.352; Length: Intersection: F = 2.047, P = 0.196).
subset of dendritic spines on the labeled D1-MSNs (Fig. 3a,c). Importantly, immunohistochemical detection of MORF-labeled neurons (Fig. 3d,e) appears to show better resolution of single labeled MSNs compared to the traditional Golgi staining, which shows more clustered MSNs in the striatum (Fig. 3f). We next examined axonal labeling in Drd1a-bacMORF striatum, and found only the proximal axonal segments of D1-MSNs can be visualized upon immunofluorescent staining (Supplementary Fig. S3).

Finally, to quantitatively assess whether MORF-labeled D1-MSNs reveal comparable dendritic architecture compared to those labeled using a traditional method, we performed 3D reconstruction and Sholl analyses of the dendritic trees of D1-MSNs labeled by Drd1a-bacMORF mice and those with biocytin microinjection in Drd1a-BAC-GFP mice (Fig. 3g,h). The comparison did not reveal any significant differences in dendritic branching patterns and length between D1-MSNs labeled by the two methods. This result showed not only that the MORF method can reveal detailed dendritic structures of D1-MSNs, but also that membrane-tethered GFP with its N-terminal polyglycine tag (encoded by G₃n repeat) does not appear to be toxic to or alter the dendritic morphology of labeled neurons.

The endogenous Drd1a receptor is expressed in other neuronal populations, such as hippocampal pyramidal neurons and dentate gyrus granule cells, therefore we examined these cells. Indeed, we found individually labeled hippocampal pyramidal neurons and dentate gyrus granule neurons (Supplementary Fig. S4) in Drd1a-bacMORF mice. Thus, our study demonstrates that the MORF method can confer genetically directed sparse neuron labeling in multiple neuronal cell types in the brain.

To demonstrate the utility of the MORF method to study neurodevelopment, we next examined postnatal changes in dendritic structures of the sparsely labeled D1-MSNs. Although prior studies using Golgi or dye injection methods have shown that striatal MSNs undergo extensive postnatal dendritic growth11–17, no prior study has examined postnatal dendritic development of identified D1-MSNs. We imaged and reconstructed detailed dendritic structures of labeled D1-MSNs in the MORF mice at postnatal days 0, 14, 30 and 90 (Fig. 4). We performed dendrogram (Fig. 4b,e,h,k) and Sholl analyses (Fig. 4c,f,i,l) of the dendritic branching patterns of multiple reconstructed D1-MSNs at each age (N > 5 per age). Our study reveals that the dendritic arbors of D1-MSNs undergo robust growth in terms of branching points, length, and diameter from birth to P30, with relatively modest dendritic growth being seen between P30 and P90. Our study demonstrates the utility of the MORF method to study dendritic development in a genetically-defined neuronal cell type in vivo.

A potentially powerful application for genetically directed sparse neuronal labeling is to study neuropathology, such as neurodegeneration, at single cell resolution. Mouse models of neurodegenerative disorders often exhibit partial disease phenotypes (e.g. neuronal atrophy) but often lack frank neuronal loss18–20. In Huntington’s disease (HD), the striatal MSNs in both the direct and indirect pathways undergo massive cell loss21. In mouse models of HD, such as the heterozygous zQ175 knockin mice expressing full-length endogenous murine mutant Huntingtin (mHtt), recapitulate the progressive striatal MSN dysfunction measured by electrophysiology22,23 and transcriptome profiling24. However, the zQ175 mice do not show significant striatal MSN loss by 12 months of age24,25. Although neurodegeneration in such models can manifest partially as degeneration of neuronal processes, the use of traditional methods, such as Golgi staining or biocytin microinjection into MSNs, did not reveal any significant MSN dendritic pathology at 7 and 12 months of age in zQ175 mice22,23. However, these methods could not distinguish MSN subtypes (D1- vs D2-MSNs), hence it is unclear if examining MSN subtypes could reveal evidence of dendritic pathology in this HD mouse model.

We reasoned that the use of Drd1a-bacMORF mice to selectively visualize D1-MSN dendrites may provide a simple and potentially sensitive method to detect early, MSN-subtype specific dendritic pathology in an HD mouse model. We crossed Drd1a-bacMORF mice to zQ175 heterozygous mice (in C57BL/6 background), and then analyzed double transgenic mice carrying Drd1a-bacMORF and zQ175 heterozygous alleles as well as Drd1a-bacMORF controls at presymptomatic age (1–2 m) or a symptomatic age (6–7 m) with motor deficits but no prior known neuropathology22,25. We imaged and reconstructed MORF-labeled D1-MSNs in the striata of these mice and quantified the dendritic parameters using Sholl analyses (Fig. 5). At the pre-symptomatic age, we found that dendritic branches, length and diameters of the labeled D1-MSNs were comparable between zQ175 and control mice (Fig. 5c–e, N = 12 per genotype from three littermates at the same age, for genotype difference, intersections: F = 0.288, P = 0.597; Length: F = 0.288, P = 0.597; Dendritic diameter: F = 0.002, P = 0.967). Interestingly, at an symptomatic age of 6-7 months, we found a statistically significant reduction of dendritic branching, length and diameter in the MORF labeled D1-MSNs in zQ175 striata compared to those from wildtype controls (Fig. 5f–h, N = 15 per genotype from three littermates at the same age, for genotype difference, intersections: F = 20.549, P < 0.05; Length: F = 26.828, P < 0.01; Dendritic diameter: F = 21.247, P < 0.05). To our knowledge, this is the first report of MSN subtype-specific dendritic pathology at such an early age in a full-length mHtt expressing mouse model. Moreover, unlike some traditional single-cell labeling methods that are incompatible with double immunofluorescent staining (e.g. Golgi), we showed MORF method can be readily combined with a second antibody to detect additional HD-like pathology such as mHtt aggregation (Supplementary Fig. S5). Future studies would be interesting to examine the relationship of such molecular pathology to dendritic phenotypes in D1-MSNs of HD mice.

**Discussion**

In summary, we describe here a conceptually novel method (MORF), based on the mononucleotide repeat frameshift mechanism, to enable the use of a single BAC transgene, with proven neuronal cell-type promoter activity in vivo, to sparsely and stochastically label genetically-defined neurons for detailed morphological studies. As a proof-of-concept study, we showed the MORF method allows a Drd1 BAC transgene to express a membrane-bound fluorescent maker protein in about 1% of D1-MSNs, which allows visualization of their dendritic architecture, development, degenerative pathology in an HD mouse model. Importantly, the latter study, to our knowledge, is the first report of MSN subtype-specific dendritic pathology in a full-length mHtt expressing
Figure 4. Using Drd1a-bacMORF Mice to Image Postnatal Dendritic Development in Striatal D1-MSNs.
The MORF method reveals the postnatal growth of dendritic arbors in single D1-MSNs at postnatal day 0 (a–c),
15 (d–f), 30 (g–i) and 90 (j–l). Individual labeled neurons were 3D reconstructed using Neurolucida (a,b,c,d),
which were then used for Dendrogram (e,f,g,h) and Sholl Analyses (i,j,k,l) to obtain quantitative morphological
data for the D1-MSNs at these different ages.
HD mouse model. At least in this case, MORF is proven to be more sensitive to detect such pathology than the traditional Golgi staining or biocytin microinjection approaches in the same HD mouse model.

In principle, the MORF reporter can be used in conjunction with other defined genetic promoters (e.g. BAC transgenes or knock-in to endogenous loci) to achieve sparse labeling of genetically-defined cell types, but future studies are needed to thoroughly evaluate the broad utility of such an approach. Since the frequency of mononucleotide repeat frameshift depend on repeat types (e.g. Cn and Gn repeats have higher frequencies than An or Tn repeats) and length, the test of additional repeat types and lengths may also expand the applications of MORF technology to achieve different labeling efficiencies for optimal studies of different neuronal populations.

Finally, strategies to enhance the MORF reporter signals, such as the use of stronger promoters, transcriptional amplification mechanisms, and reporters with enhanced detection signals, may improve the use of MORF to visualize more complete morphology of labeled single neurons. Ideally, it would include synaptic structures, dendritic trees, and brain-wide axonal projections. In conclusion, our study provides important proof-of-concept for a novel genetic approach to label and study the morphological details of genetically-defined single neurons.

Figure 5. Using Drd1a-bacMORF Mice to Visualize Dendritic Pathology in an Huntington’s Disease Knock-in Mouse Model. Drd1a-bacMORF mice were crossed with an HD knock-in mouse model expressing full-length mHtt with 175Q from its endogenous locus. Single labeled D1-MSNs in both wildtype and zQ175 heterozygous mice were examined at 1–2 months and 6–7 months of age, reconstructed using Neurolucida, and subsequently quantified using Sholl analysis. (a) D1-MSNs in wildtype mice at 6–7 m of age. (b) An example of MORF-labeled D1-MSNs with aberrant dendritic pathology in zQ175 mouse striatum at 6–7 m of age. (c–e) Scholl analyses of reconstructed D1-MSNs at 1–2 m of age do not show significant difference in dendritic branching pattern (i.e. intersection), length or diameter between wildtype and zQ175 heterozygous mice (two-way ANOVA, p > 0.05, (c,d,e)). (f–g) There is a statistically significant reduction of dendritic branching, length and dendrite diameter in MORF-labeled D1-MSNs in zQ175 heterozygous mice at 6–7 months of age compared to wildtype mice at the same age (two-way ANOVA, p < 0.05).
which should facilitate the study of how neuronal morphology may be causally linked to normal function, or dysfunction and degeneration in the mammalian brain.

### Methods

#### Generation of Drd1α-bacMORF-GFP BAC Transgenic Mice.

A 200 kb murine Dopamine Receptor 1 (Drd1α) BAC (RP23-47M2) used in GENSAT was obtained from the BACPAC resource center (Oakland Children's Hospital, Oakland). The transgene that contains the mononucleotide tract (G22), followed by a farnesylated-GFP coding and polyA region was inserted into exon 1 of Drd1α preceding the endogenous translation initiation codon (Fig. 1a). Two oligonucleotides were synthesized and annealed to generate G22 mononucleotide tract (Oligo1: 5′-CTCGAGGCCCCATGGGGGGGGGGGGGGGGGGGAAGCTT-3′; Oligo 2: 5′: AAGCTTCCCCCCCCCCCCCCCCCCCCCATGGTGGCCTGAG-3′) flanked by two restriction enzyme (Xhol and HindIII) sites to create a frame shift mutation for farnesylated GFP. Maxiprep DNA was prepared from the modified Drd1α BAC and purified through cesium prep. The integrity of the BAC DNA was examined on a pulsed-field gel according to an established protocol. The intact BAC DNA (1 ng/ul) was microinjected into fertilized F1 mouse (C57BL/6/CBA) zygotes to generate BAC transgenic mice. Two of the D1-MORF BAC transgenic lines, designated lines A and B, were subsequently germline transmitted and expanded by crossing with wildtype C57BL/6 mice. The heterozygous transgenic mice and their wildtype littermates were used for all subsequent studies. Mouse care in the current study was in accordance with the United States Public Health Service Guide for the care and Use of Laboratory Animals. The procedures were approved by Chancellor’s Animal Research Committee (ARC) at UCLA. Veterinarian care was provided by the UCLA Division of Laboratory Animal Medicine. Animals were housed in a specific-pathogen-free barrier facility at UCLA, with up to four mice per cage with food and water available ad libitum. They were housed in a temperature-controlled environment with 12 hour light/dark cycle.

#### Transgene copy number determination by quantitative PCR.

Tail genomic DNA was extracted using phenol-chloroform (Sigma-Aldrich) with ethanol precipitation. Quantitative PCR was performed using the KAPA SYBR Fast qPCR mix with primer sets targeting the 3′UTR in Exon of Drd1α (For: AAA GTT CCT TTA AGA TGT CCT; Rev: TGG TGG CTG GAA AAT AGA A) and the housekeeping gene HPRT (Forward: GCT CGA GAT GTC ATG AAG GAG A; Reverse: TCA GTG CTT TAA TGT AAT CCG A) as reference for normalization. PCR reactions were carried out on a Roche LightCycler 480 with the following cycling conditions for all primer sets: 95 °C for 3 min and then 40 cycles of 95 °C for 15 sec, 56 °C for 25 sec, and 72 °C for 1 sec, followed by a melting curve analysis and 40 °C for 10 sec. All samples were run in three replicates for each primer set. Using the 2−ΔΔCt relative expression method, the average CT values for the three replicates of each gene was normalized to the average CT values for the housekeeping gene (HPRT) to calculate the expression level of Drd1α in the transgenic mice relative to WT mice.

#### Immunofluorescence and Imaging.

Drd1α-bacMORF transgenic mice were perfused transcardially with 4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS). Tissues were isolated and fixed in 4% PFA in 0.1 M PBS at 4 °C overnight and cryoprotected for >24 hours in 30% sucrose in PBS, then embedded in Tissue-Tek OCT (VWR, Cat. No 25608-930) prior to cryostat sectioning. Tissues were sectioned at 20 μm on a Leica 1800 Cryostat (Deerfield, IL) and cryoprotected for further usage. Floating sections were immunostained in 24-well plates using the procedures below and subsequently mounted on slides. For immunofluorescence, cryosections were washed three times for 10 min in PBS, blocked with 10% normal goat serum (GS) in PBS + 0.3% Triton X-100 (PBT) for 1 hour at room temperature, and stained at 4 °C overnight with primary GFP antibodies in 5% GS in PBT (1:500 dilution). Following four washes for 10 min in PBT, sections were stained for 1 hour with secondary antibodies. The sections were washed four times for 10 minutes with PBT, treated with DAPI (Sigma, Cat. No. D96417), rinsed for 10 minutes in PBS, and mounted in Fluoro-Gold mounting medium. Some synapse images were taken with immunofluorescence staining with the standard Tyramide Signal Amplification (TSA, PerkinElmer) protocol.

For imaging D1-MORF labeled axons, 60 μm thick sagittal brain sections were cut and washed in 0.01 M PBS three times, each for 10 min. The sections were blocked with 10% GS in PBS with 0.3% Triton X-100 (PBT) for 1 hour, then incubated in PBT with rabbit anti GFP antibody (1:5000, Life Tech) for 48 hours at 4 °C. Following four washes for 10 min each in PBT, sections were stained for 2 hours with goat anti-rabbit antibody (1:1000, Vector Laboratories) at room temperature or overnight at 4 °C with shake. The sections were then washed four times with PBT for 10 minutes each, processed with TSA amplification, and subsequently incubated in Alexa Fluor® 594-streptavidin (1:500, Vector Laboratories). Images were taken using an LSM510 confocal system (Carl Zeiss Inc., Oberkochen, Germany) or a Zeiss fluorescence microscope with a CCD camera and processed using LSM software (Zeiss) and ImageJ.

#### 3D Neuronal Reconstruction and Quantification of Dendritic Morphology.

To visualize the refined structures of D1-MSNs, Neurolucida (MicroBrightField, Williston, Vermont) was used to trace dendritic arbors of MSNs three-dimensionally and to mark spines. A cell was rejected if the soma was not intact or if it displayed discontinuity of processes, suggesting compromised integrity. Serial optical sections (Z-stacks) were acquired on a laser-scanning confocal microscope (LSM 510; Zeiss) with a 40×/1 NA objective (Zeiss). Images were stored at 8-bit image depth at a resolution of 512 × 512 pixels (0.22 × 0.22 × 1 μm). Z-series of the same cell were stitched together and subsequently reconstructed and analyzed using the MicroBrightField Neurolucida/Neuroexplorer suite.

#### Statistical analysis.
All statistical analyses were performed using the SPSS statistics (Version 22.0, IBM). For each of the basic morphometric parameters (intersections, length, and dendritic diameter), we tested for
significant differences between genotype (H0: a given parameter does not significantly differ across distance from the soma). Each measurement was first tested for goodness of fit to a normal distribution within each age group using the Lilliefors test (α = 0.05). Where normality could be assumed, a student’s t-test or one-way analysis of variance (ANOVA) was used to test for differences across groups, followed by a Least Significant Difference (LSD) post-hoc multiple-comparison test to test for specific differences between groups (α = 0.05). Where normality could not be assumed, a Mann-Whitney U test or Kruskal–Wallis non-parametric ANOVA was used to test for differences across groups followed by post-hoc multiple comparisons t-tests (LSD-adjusted, α = 0.05). Outliers were detected using the Explore function in SPSS and excluded form analysis. For Sholl analyses in zQ175 mice, either total dendrite length or total number of intersections within each shell was compared using a two-way ANOVA, with genotype and distance from the soma as factors (H0: a given parameter does not significantly differ across distance from the soma).

References
1. Luo, L., Callaway, E. M. & Svoboda, K. Genetic dissection of neural circuits. Neuron 57, 634–660, doi: 10.1016/j.neuron.2008.01.002 (2008).
2. Jefferis, G. S. & Livet, J. Sparse and combinatorial neuron labelling. Current opinion in neurobiology 22, 101–110, doi: 10.1016/j.conb.2011.09.010 (2012).
3. Gong, S. et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425, 917–925 (2003).
4. Li, Y. C., Korol, A. B., Fahima, T. & Nevo, E. Microsatellites within genes: structure, function, and evolution. Mol Biol Evol 21, 991–1007 (2004).
5. Orr, H. T. & Zoghbi, H. Y. Trinucleotide Repeat Disorders. Annu Rev Neurosci 30, 51–62 (2007).
6. Bhargava, A. & Fuentes, F. F. Mutationary dynamics of microsatellites. Molecular biotechnology 44, 250–266, doi: 10.1007/s12033-009-9230-4 (2010).
7. Rampino, N. et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275, 967–969 (1997).
8. Hersh, M. N., Stambrook, P. J. & Stringer, J. R. Visualization of mosaicism in tissues of normal and mismatch-repair-deficient mice carrying a microsatellite-containing transgene. Mutation research 505, 51–62 (2002).
9. Stringer, J. R., Larson, J. S., Fischer, J. M. & Stringer, S. L. Increased mutation in mice genetically predisposed to oxidative damage in the brain. Mutation research 556, 127–134, doi: 10.1016/j.mrfmmm.2004.07.010 (2004).
10. Fischer, J. M. & Stringer, J. R. Mutation in aging mice occurs in diverse cell types that proliferate postmutation. Aging cell 7, 667–680, doi: 10.1111/j.1474-9726.2008.00416.x (2008).
11. Miller, A. J., Dudley, S. D., Tsao, J. L., Shibata, D. & Liskay, R. M. Tractable Cre-lox system for stochastic alteration of genes in mice. Science 275, 967–969 (1997).
12. Tepper, J. M., Sharpe, N. A., Koos, T. Z. & Trent, F. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 mice and cerebral microvascularization and blood flow in the Q175 mouse model of Huntington's disease. J Neurosci 34, 631–645, doi: 10.1016/j.neuroscience.2010.04.031 (2010).
13. Nelson, A. B. & Kreitzer, A. C. Reassessing models of basal ganglia function and dysfunction. Annu Rev Neurosci 37, 117–135, doi: 10.1146/annurev-neuro-071013-013916 (2014).
14. Shuen, J. A., Chen, M., Gloss, B. & Calakos, N. Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J Neurosci 28, 2681–2685 (2008).
15. Adinolfi, A. M. The postnatal development of the caudate nucleus: a Golgi and electron microscopic study of kittens. Brain Res 133, 251–266 (1977).
16. Tepper, J. M., Sharpe, N. A., Koos, T. Z. & Trent, F. Postnatal development of the rat neostriatum: electrophysiological, light- and electron-microscopic studies. Developmental neuroscience 20, 125–145 (1998).
17. Rafols, J. A., Cheng, H. W. & McNeill, T. H. Golgi study of the mouse striatum: age-related dendritic changes in different neuronal populations. The Journal of comparative neurology 279, 212–227, doi: 10.1002/cne.902790205 (1989).
18. Crook, Z. R. & Housman, D. Huntington's disease: can mice lead the way to treatment? Neuron 69, 423–435, doi: 10.1016/j.neuron.2010.12.035 (2011).
19. Ashe, K. H. & Zahs, K. R. Probing the biology of Alzheimer's disease in mice. Neuron 66, 631–645, doi: 10.1016/j.neuron.2010.04.031 (2010).
20. Dawson, T. M., Ko, H. S. & Dawson, V. L. Genetic animal models of Parkinson's disease. Neuron 61, 646–661, doi: S0896-6273(10)00327-2 [pii] 10.1016/j.neuron.2009.10.005 (2010).
21. Vonsattel, J. P. & DiFiglia, M. Huntington disease. J Neuropathol Exp Neurol 57, 369–384 (1998).
22. Heikkenen, T. et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One 7, e50717, doi: 10.1371/journal.pone.0050717 (2012).
23. Sondersmiten, T., Tran, C. H., Cepeda, C. & Levine, M. S. Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease. J Neurophysiol 113, 2953–2966, doi: 10.1152/jn.01056.2014 (2015).
24. Langfelder, P. et al. Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci 19, 623–633, doi: 10.1038/nn.4256 (2016).
25. Smith, G. A. et al. Progressional axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum Mol Genet 23, 4510–4527, doi: 10.1093/hmg/ddu66 (2014).
26. Bayram-Weston, Z., Osen, E., Harrison, D. I., Dunnett, S. B. & Brooks, S. P. Optimising Golgi-Cox staining for use with perfusion-fixed brain tissue validated in the zQ175 mouse model of Huntington's disease. Journal of neuroscience methods 265, 81–88, doi: 10.1016/j.jneumeth.2015.09.033 (2016).
27. Boyer, J. C. et al. Sequence dependent instability of mononucleotide microsatellites in cultured mismatch repair proficient and deficient mammalian cells. Human molecular genetics 11, 707–713 (2002).
28. Madisen, L. et al. Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. Neuron 85, 942–958 (2015).
29. Shiner, N. C. et al. A bright monomeric green fluorescent protein derived from Branchiostoma lampasolatum. Nat Methods 10, 407–409 (2013).
30. Gong, S. & Yang, X. W. Modification of Bacterial Artificial Chromosomes (BACs) and Preparation of Intact BAC DNA for Generation of Transgenic Mice. Current Protocols in Neuroscience (2005).
31. Liva, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408, doi: 10.1006/meth.2001.1262 (2001).
Acknowledgements
We would like to thank Dr. Larry Zipursky for helpful discussions. Drs. Xiaofeng Gu, Nan Wang, Chris Park at Yang lab and Hongwei Dong (USC) for assistance in acquiring some images, and members of Yang lab for proofreading of the manuscripts. The research is supported in part by NIH BRAIN Initiative award (NIMH/NIH Grant U01-MH106008) and by NIDA/NIH grant (P50 DA005010). X.W.Y. is also supported by the NINDS/NIH grants (NS049501 and NS074312, NS084298), the Leslie Gehry Brenner Prize from Hereditary Disease Foundation (HDF), CHDI Foundation, the Neuroscience of Brain Disorders Award from The McKnight Foundation, the David Weil Fund to the Semel Institute at UCLA, and the Carol Moss Spivak Scholar in Neuroscience award from the UCLA Brain Research Institute. X.-H.L. is supported by NARSAD Young Investigator Award.

Author Contributions
X.W.Y. and X.-H.L. designed the experiments, interpreted the data and wrote the manuscript. X.-H.L. carried out the experiments and made Figs 1–7 and Supplementary Figs S1–S5.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing Interests: The authors declare no competing financial interests.

How to cite this article: Lu, X.-H. and Yang, X. W. Genetically-directed Sparse Neuronal Labeling in BAC Transgenic Mice through Mononucleotide Repeat Frameshift. Sci. Rep. 7, 43915; doi: 10.1038/srep43915 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017